From Reactive to Proactive Care: Using AI to Detect Gender-Based Violence in Brazil - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Using AI to Identify Gender-Based Violence in Brazilian Health Records and Enable Earlier Intervention

  • By

  • Luke Taylor

  • October 19, 2026

Share

Clinical Scorecard: Using AI to Identify Gender-Based Violence in Brazilian Health Records

At a Glance

CategoryDetail
ConditionGender-based violence (GBV) and femicide in Brazil
Key MechanismsClarIA analyzes clinical notes and medical histories for semantic patterns resembling records of confirmed GBV, rather than searching for isolated keywords. It issues amber or red alerts for clinical review.
Target PopulationWomen receiving care at participating clinics and hospitals in Recife, Brazil
Care SettingHealth care clinics and hospitals using ClarIA to flag possible unreported GBV

Key Highlights

  • A pilot investigation examined 13,000 formally documented GBV cases in Recife.
  • Women’s health care visits occurred an average of 92 days before GBV was recorded in their cases.
  • ClarIA uses amber alerts for patterns resembling those in confirmed GBV records and red alerts for prior disclosure or identification by a health professional.
  • After deployment began in Recife, 39 clinics and hospitals were using ClarIA, and health professionals submitted eight GBV notifications after receiving alerts.

Guideline-Based Recommendations

Diagnosis

  • The article describes ClarIA alerts as prompts for closer review, not as diagnoses.
  • The article says the tool identifies patterns across clinical narratives rather than isolated terms.

Management

  • Clinicians receiving alerts undergo training in ethical, sensitive care that safeguards patients’ rights and privacy.
  • The article describes workflows for subsequent actions, including referral to specialists or contacting protective services when circumstances warrant.

Monitoring & Follow-up

  • The article reports limited available data because ClarIA is new.
  • Following rollout, health professionals formally submitted eight GBV notifications after receiving alerts.

Risks

    Patient & Prescribing Data

    The Recife pilot examined 13,000 formally documented GBV cases. ClarIA is being deployed in clinics and hospitals in Recife.

    ClarIA is an alerting tool, not a treatment or diagnostic system. Alerts prompt clinical review and may be followed by specialist referral or contact with protective services when circumstances warrant.

    Clinical Best Practices

    • The article describes alerts as prompts for closer review, not confirmation of GBV.
    • The article reports that clinicians receiving alerts are trained in ethical, sensitive care that safeguards patients’ rights and privacy.
    • The article describes workflows for appropriate next steps, including referral or protective-service contact when circumstances warrant.

    Related Resources & Content

      Original Source(s)

      Related Content